Nature Rev. Cancer 5, 341–354 (2005)
The authors would like to correct Figure 4b of this article. The statement in the figure legend that reads “The epidermal growth factor receptor variant III (EGFRvarIII) cannot bind cetuximab or matuzumab” is incorrect. Wu and colleagues1 have shown that cetuximab does bind EGFRvarIII. Furthermore, Li and colleagues2 have demonstrated that X-ray crystal structure data of the cetuximab–EGFR complex show that cetuximab recognizes an epitope that is present in EGFRvarIII. Matuzumab also binds EGFRvarIII (W. Wels and C. Hartmann, unpublished observations).
References
Wu, G. et al. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconjugate Chem. 15, 185–194 (2004).
Li, S. et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7, 301–311 (2005).
Additional information
The online version of the original article can be found at 10.1038/nrc1609
Rights and permissions
About this article
Cite this article
Hynes, N., Lane, H. Correction: ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors. Nat Rev Cancer 5, 580 (2005). https://doi.org/10.1038/nrc1667
Issue Date:
DOI: https://doi.org/10.1038/nrc1667
